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Abstract
Major Depressive Disorder is the leading cause of disability among mental illnesses
worldwide, but existing therapies fail to adequately treat approximately 30-50% of
depressed patients. Ketamine has promising rapid antidepressant effects, but these effects
are of short duration. Exercise yields moderate antidepressant effects both as a primary
treatment and as an adjunct to standard therapies, but has not been investigated as an
adjunct to ketamine. This study seeks to determine whether the addition of regular
aerobic exercise regimens to ketamine therapy will potentiate or prolong ketamine’s
antidepressant effects. We propose a single-blind, randomized controlled trial in which
patients will be randomly assigned to receive intravenous ketamine or ketamine plus a
structured exercise regimen. The potentiation or prolongation of ketamine’s
antidepressant effects with exercise may increase the number of patients responsive to
therapy and may reduce the cost and potential adverse effects of ketamine therapy.
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CHAPTER 1: INTRODUCTION
Background
Major Depressive Disorder (MDD) is a highly prevalent and potentially debilitating
disorder accounting for significant disability, morbidity, and mortality worldwide.1 It is
estimated that the lifetime prevalence of MDD in the United States is 16.9%, and globally
it is the leading cause of disability among mental illnesses.2 The World Health
Organization (WHO) reports that depression is the fourth leading cause of disability
among all diseases worldwide, and projects that it will become the second leading cause
of disability among all illnesses by 2020.1 MDD disproportionately affects women,
affecting approximately twice as many women as men; this relationship has been
observed in numerous countries worldwide.1 In the United States, individuals with the
lowest incomes are twice as likely to be depressed as those with the highest incomes1. It
has been estimated that between 1/3 and 1/2 of patients with MDD experience a recurrent
major depressive episode (MDE) in a given year1. Importantly, MDD has been associated
with increased risk and severity of numerous medical conditions, an elevated risk of early
death, and risk of suicide.1
Clinical Presentation and Diagnosis of Major Depressive Disorder
The clinical presentation of MDD varies significantly; each individual presents with a
unique pattern of signs and symptoms that occurs over a particular temporal pattern.3
MDD is characterized by the presence of one or more MDEs, in which an individual
experiences an assortment of emotional, cognitive, and somatic symptoms over the
course of at least two weeks.4 According to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-5), the core symptoms of MDD that commonly manifest during
1

a MDE include: depressed mood, loss of interest or pleasure in usual activities, feelings
of guilt or worthlessness, fatigue, difficulty concentrating, change in appetite or weight,
psychomotor agitation or retardation, insomnia or hypersomnia, and suicidal ideation or
suicide attempt.5 These symptoms are typically present on a daily basis and may be either
newly present or worsening from an individual’s baseline.4 One study found that the most
commonly reported symptom of MDD is depressed mood, followed by changes in sleep
habits and difficulty concentrating.3 The impact of MDD can be far-reaching and may
negatively affect an individual’s sleep habits, diet, interpersonal relationships,
occupation, or education.
The diagnosis of MDD is made using a set of diagnostic criteria outlined in the DSM-5.5
Five of the nine symptoms listed above must be present or worsening within the same
two week period, and one of the presenting symptoms must be either depressed mood or
loss of interest in one’s usual activities.4,5 Importantly, symptoms must not be better
explained by the effects of a medical condition and must lead to significant psychosocial
distress or impairment in order to qualify for a diagnosis of MDD.4
Clinicians frequently utilize screening tools to facilitate the accurate diagnosis of MDD,
to develop treatment plans, and to monitor progress throughout the course of a patient’s
treatment.6 The Patient Health Questionnaire-9 (PHQ-9) is a screening tool commonly
used in clinical settings. It is convenient for clinicians in that it is relatively brief, is
completed by patients, and that each item on the questionnaire correlates with a
diagnostic criterion for MDD as outlined in the DSM-5.6 The Montgomery- Åsberg
Depression Rating Scale (MADRS) is another screening tool which was specifically
designed to detect changes in depression scores over the course of receiving
2

antidepressant treatment.7 The MADRS is commonly used in clinical research settings
due to its high sensitivity in detecting changes in depression scores over time as well as
its high inter-rater reliability.8
Given the broad range of symptoms that characterize MDD, there is significant
heterogeneity in the clinical presentation of patients with MDD.9 Six of the diagnostic
criteria outlined in the DSM-5 are considered to be compound because they consist of
several symptoms (e.g. “insomnia or hypersomnia” is listed as a single diagnostic
criterion).9 When each individual symptom within the compound diagnostic criteria was
considered, there are 14,528 different combinations of symptoms that meet diagnostic
criteria for MDD.9 This lends credence to the notion that what we consider to be MDD
may actually represent a spectrum of distinct disorders, each with unique neurobiological
underpinnings that have yet to be elucidated.3
MDD is a recurrent disorder in which the majority of affected individuals experience a
relapsing and remitting course.5 There is a significant degree of individual variation in the
clinical course of MDD; many individuals experience depressive episodes lasting weeks
to months, while others continue to experience symptoms for years at a time without
relief.5 The median age of onset for MDD in the United States is 22.7, but the range is
wider than that observed in other mental disorders and onset at a younger or older age is
not uncommon.1 Earlier onset of MDD in childhood or adolescence has been associated
with a more severe course including increased risk of suicide, more severe symptoms,
increased comorbid psychiatric disorders, as well as a more chronic course with more
recurrent MDEs.10 Recurrence is quite common in MDD, with an estimated 31% of
patients experiencing a recurrent MDE in a given year in primary care populations.11
3

Additionally, the number of previous MDEs has been associated with an increased risk of
recurrence,11 indicating that each MDE increases the risk of experiencing a subsequent
MDE. Subclinical residual symptoms that persist beyond a MDE are another predictor for
future recurrence of a subsequent MDE.11 Individuals who experience residual symptoms
following remission of a MDE are more likely to relapse into a subsequent MDE, and
relapse more quickly than individuals who relapse but did not experience residual
symptoms.3 The most common residual symptoms include fatigue, difficulty
concentrating, forgetfulness, and indecisiveness; these symptoms are less likely to be
apparent to clinicians as they are difficult to note objectively and patients may not
recognize that they are symptoms related to MDD.3
MDD is the most common psychiatric disorder among individuals who commit suicide,12
which represents the most dire consequence of the disease. The WHO estimates that
approximately one million people die annually as a result of suicide.13 Suicide represents
the fourth-leading cause of death among individuals aged 10-65 and the third-leading
cause of death among children aged 10-14 in the United States.13,14 While completed
suicide garners a great deal of attention, unsuccessful suicide attempts and suicidal
ideation account for numerous emergency department visits and admissions to psychiatric
inpatient institutions every year.13 Taken together, these statistics highlight that suicide
represents a major public health concern and, like MDD overall, is not being adequately
addressed by currently available psychiatric treatments.
Overview of Proposed Etiologies for Major Depressive Disorder
While a number of risk factors have been identified, the etiology of MDD has been
elusive and there is presently a lack of consensus regarding the neural and psychosocial
4

underpinnings of the disease despite a large body of research devoted to its study. The
etiology of MDD is clouded by the heterogeneity of its clinical presentation, course, and
response to treatment.
The monoamine hypothesis has classically been accepted as the most commonly held
theory regarding the etiology of MDD.15 This theory posits that deficiencies in levels of
the monoaminergic neurotransmitters serotonin, norepinephrine, and dopamine within
diffuse brain regions are the underlying cause of MDD.15 Several types of antidepressants
including monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin
reuptake inhibitors, and selective norepinephrine reuptake inhibitors were developed on
the basis of this theory with the intent of increasing synaptic concentrations of
monoaminergic neurotransmitters as a means of treating MDD.16 This theory is flawed,
however, in that it is incapable of properly explaining the delayed response to
antidepressant medication and the significant proportion of depressed individuals that fail
to respond to antidepressants.15
More recent research has implicated that dysfunction in a number of more specific brain
regions and neural circuits may possibly underlie the various manifestations of MDD. A
common hypothesis is that chronic stress causes hypothalamic-pituitary-adrenal (HPA)
axis dysfunction, leading to chronic elevations of glucocorticoids which has been
proposed as an explanation for reduced hippocampal volumes that have been observed in
individuals with MDD.15 Other research indicates that the various symptoms of MDD
may be the result of impaired functional connectivity causing dysfunction in several
discrete brain regions, involving numerous neurotransmitters including monoamines as
well as histamine, acetylcholine, and glutamate.3,17 More recently, the prefrontal cortex
5

has been identified as a region where impaired functional connectivity may likely occur,
potentially explaining alterations in executive functions commonly seen in MDD as well
as impaired emotional regulation as a result of loss of top-down regulation of circuitry
within the limbic system.18
Overview of Standard Treatments for Major Depressive Disorder
Monoaminergic drugs such as selective serotonin reuptake inhibitors (SSRIs) and
selective serotonin-norepinephrine reuptake inhibitors (SNRIs) are currently the standard
of care for pharmacologic treatment of depression. Approximately 60-70% of patients
experience clinically significant symptom relief with currently available
pharmacotherapies, but this figure includes patients that may require up to four different
treatment steps after failing to respond to first-line medications.19 It is noteworthy that
only one-third of patients respond fully to antidepressant medication; large clinical trials
have shown that half of patients fail to demonstrate at least a 50% reduction in depressive
symptoms after undergoing 12-14 weeks of treatment.19 The latency in onset of
antidepressant medications is well-documented; many patients require weeks to months
to attain clinically significant symptom improvement, and sustained remission of
depressive symptoms in the long term is not common.2 The side effect profile of
antidepressant medications of all pharmacologic classes are significant and welldocumented, rendering them intolerable for a significant portion of patients.20 Taken
together, this speaks to the notion that the efficacy of currently available
pharmacotherapies for MDD is limited, which leaves many patients with inadequate or
no symptom relief.
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Psychotherapies such as cognitive behavioral therapy (CBT) are proven to have similar
efficacy as pharmacologic therapies,21 and psychotherapy in combination with
pharmacotherapy has been proven to be more effective than either treatment alone.22
While generally considered to be cost-effective, psychotherapy frequently poses
significant out-of-pocket costs for patients and is therefore either not accessible or only
available in suboptimal durations to a significant portion of patients.23 Due to the
shortcomings in efficacy and accessibility of current antidepressant treatments, a
significant portion of patients with MDD either achieve suboptimal or no treatment for
their depressive symptoms and as a result a large body of research has been devoted to
the development of alternative therapies for MDD.
Overview of Ketamine as a Rapid-Acting Antidepressant
Ketamine is an N-methyl-D-aspartate receptor (NMDA-R) antagonist that has been used
clinically for its anesthetic, sedative, and analgesic properties for over 50 years.2 As a
result of the shortcomings of traditional antidepressant treatments, ketamine has recently
received attention for its promising rapid antidepressant effects and potential to serve as
an alternative treatment option for patients with MDD.
Several randomized controlled trials (RCTs) have demonstrated that subanesthetic doses
of IV ketamine provide significant reductions in depressive symptoms, most notably in
suicidal ideation, within four hours following an infusion.24 However, ketamine’s
antidepressant effects are of short duration and tend to diminish within 7-14 days of
treatment, which poses a significant barrier to its viability as a depression treatment.24
Concerns regarding potentially harmful neurobiological side effects of ketamine limit its
potential to be used in the long-term to maintain remission of depressive symptoms.25
7

Additionally, ketamine’s potential for abuse raises many questions regarding its viability
for use on an outpatient basis for regular, long-term use – particularly in patients with a
history of substance abuse. Numerous studies have indicated that future directions in
research surrounding ketamine’s use in the treatment of MDD should be focused on
developing strategies to prolong its antidepressant effects, limiting the amount of
ketamine treatments needed to sustain its antidepressant effects.2,24
Overview of the Antidepressant Effects of Exercise for Major Depressive Disorder
The American College of Sports Medicine (ACSM) defines exercise as being purposeful
physical activity undertaken with the intention of improving one’s overall health and
fitness.26
In addition to numerous benefits on physical health, exercise has been proven to have
moderate antidepressant effects in MDD as a solitary treatment,27 with preliminary
evidence supporting its use as an adjunct to CBT,28 antidepressant medication,29 and to
the combination of CBT and pharmacotherapy.30 Importantly, exercise has been shown to
have antidepressant effects comparable to those of antidepressant medication and
psychotherapy.31 Exercise holds many advantages over pharmaceutical and
psychotherapeutic treatments for MDD in that it is less expensive, is not associated with
the numerous side effects of psychotropic drugs, and is well-established as being
effective in the prevention and treatment of several medical conditions.32
The WHO recommends the implementation of regular physical exercise, in combination
with medication or psychotherapy, as part of the standard treatment of MDD.29 Many
clinicians have embraced the utility of exercise in the treatment of depression due to its
accessibility, relatively low cost, absence of side effects, and bountiful benefits on many
8

aspects of physical health.33 Taken together, current high-level evidence supports
exercise as having moderate antidepressant effects and also supports the notion that
exercise may be an effective adjunct therapy for depression. Therefore, it stands to reason
that exercise may have the potential to augment the antidepressant effects of ketamine.
This study seeks to determine whether the addition of adjunct regular aerobic exercise
regimens to existing ketamine treatments will potentiate or prolong ketamine’s
antidepressant effects.
Statement of the Problem
The rapid antidepressant effects of ketamine are well-established, but a major limitation
of ketamine’s clinical utility is its short duration of action. While many patients achieve
clinically significant remission of symptoms within 1-4 hours of treatment, many patients
experience a relapse in depressive symptoms within 7-14 days. There is currently a
paucity of research investigating therapeutic adjuncts to ketamine therapy that may
improve its antidepressant effects or prolong its duration. Additionally, not all patients
respond clinically to ketamine treatment and few adjunct therapies to potentiate the
antidepressant effect of ketamine have been investigated to date.
Goals and Objectives
The goals of this study are to determine whether exercise regimens potentiate the initial
antidepressant response to ketamine treatment and whether regular exercise prolongs the
duration of ketamine’s antidepressant effect. The objectives of this study are to compare
reductions in MADRS scores between subjects undergoing ketamine treatment alone and
those undergoing ketamine treatment plus an exercise regimen.
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Study design: The current proposal encompasses a two-arm, single-blind, randomized
controlled trial comparing ketamine to ketamine plus an exercise regimen for the
treatment of MDD in an adult population.
Outcomes: The primary outcome will be mean reductions in MADRS scores at four
weeks of follow-up from the last ketamine infusion compared to scores recorded at
baseline. Secondary outcomes will be time to extinction of ketamine’s antidepressant
effects during follow-up, and mean reductions in depression scores immediately
following completion of ketamine therapy.
Hypothesis
The addition of adjunct aerobic exercise routines to ketamine treatment will result in
greater mean reductions in MADRS scores four weeks after completion of ketamine
treatment compared to ketamine treatment alone in adults with moderate-severe MDD.
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CHAPTER 2: REVIEW OF THE LITERATURE
Introduction
Between July 2018 and April 2019, a comprehensive review of relevant literature was
performed using the databases PubMed, Ovid PsycINFO, Scopus, and the Cochrane
Library. The literature review included articles published between the dates of 19792018; the vast majority of articles were published within the past 10 years and older
articles were included as necessary to adequately review relevant literature. The
following key search terms were utilized: “depression”, “major depressive disorder”,
“depression epidemiology”, “STAR D”, “depression clinical presentation”, “depression
ketamine”, “ketamine rapid antidepressant”, “ketamine glutamate”, “depression
exercise”, “depression aerobic exercise”, “depression adjuncts”, “exercise BDNF”,
“cognitive behavioral therapy”, “ketamine depression exercise”, and “ketamine exercise”.
This literature review includes randomized controlled trials (RCTs), systematic reviews,
critical appraisals, and meta-analyses. References were mined from the included articles
to expand and facilitate the review of relevant literature. The search was limited to
articles written in English.
Review of Empiric Studies Investigating Ketamine as a Rapid-Acting
Antidepressant with a Single Intravenous Infusion
As a result of the shortcomings of traditional treatments for major depressive disorder
(MDD), ketamine has recently received attention for its promising rapid antidepressant
effects and its potential to serve as an alternative treatment option for patients with MDD,
and particularly for patients with treatment-resistant depression (TRD). In the past 20
years, ketamine has been studied more extensively than other N-methyl-D-aspartate
13

receptor (NMDA-R) antagonists and has consistently demonstrated impressive
antidepressant effects when administered intravenously at subanesthetic doses of
0.5mg/kg in multiple independent clinical trials.1 While monoaminergic antidepressants
have been shown to produce a response rate of approximately 40-47% that takes weeks to
months to take effect, ketamine has exhibited a response rate of 65-70% that typically
takes effect within two hours of administration,2 prompting some to label its
antidepressant effects as one of the most important discoveries in psychiatry in the past
60 years.3 The primary limitation to ketamine’s utility as an antidepressant is its short
duration of action; several studies have demonstrated that ketamine’s antidepressant
effects most commonly subside within 7-14 days of administration, though the effects
persist considerably longer for some individuals.4,5 The following section will review
evidence of ketamine’s efficacy as a rapid-acting antidepressant.
Berman et al. (2000) was the first group to investigate the antidepressant effects of
ketamine in a double-blind, placebo-controlled, crossover clinical trial.6 A small sample
of eight subjects with MDD was administered either an intravenous (IV) infusion of
ketamine (0.5mg/kg) over 40 minutes, or a saline placebo administered intravenously
over the same period. Consistent with the crossover design, subjects received both the
ketamine and saline placebo treatments in a randomized order, at least one week apart.
Changes in depression scores on the 25-item Hamilton Depression Rating Scale (HDRS)
following each treatment were compared as the primary outcome; baseline scores
measured prior to treatment were compared to scores over the following 72 hours.6
Treatment with ketamine resulted in significantly greater reductions in HDRS scores than
treatment with placebo.6 Analyses of variance using the Huynh-Feldt correction revealed
14

significant condition-by-time effects (F = 3.97, d.f. 5,30, p = .02), but insignificant time
effects (F = 2.62, d.f. 5,30, p = .09) and condition effects (F = 0.157, d.f. 1,30, p = .71).
This revealed impressive reductions in HDRS scores from baseline at each subsequent
time point. 50% of subjects exhibited a 50% or greater reduction in HDRS scores at 72
hours post-infusion, while only 12.5% of subjects exhibited such a reduction in HDRS
scores following a placebo treatment. The improvements in depression scores due to
ketamine treatment reportedly returned to baseline within 7-14 days, though this study
was not designed to detect the temporal scale of these changes. Statistically significant
reductions, measured with paired t-tests, were noted for the following measures on the
HDRS among all subjects: suicidality (p=.02), depressed mood (p=.0025), worthlessness
(p=.015), and helplessness (p=.008).6
As a result of the design of this study, some subjects received ketamine seven days prior
to receiving a placebo treatment. Although the duration of ketamine’s effects was not
well-characterized at the time, it is now known that ketamine’s antidepressant effects last
longer than seven days in some individuals.5 The authors noted that baseline depression
scores prior to receiving the placebo treatment were approximately 10 points lower in the
group that received ketamine first, though post hoc analyses revealed that there were no
statistically significant effects as a result of the order in which ketamine or placebo
treatments were administered.6 It is conceivable that this affected results, but an effect
was unable to be detected in this small sample size. The results of this study may have
been confounded by the inclusion of subjects with bipolar disorder and panic disorder.6
Despite the small sample size of this study it demonstrated impressive antidepressant
effects for ketamine, generating a great deal of subsequent research seeking to replicate
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its effects in larger trials and better characterize the temporal scale of its antidepressant
effects.
Zarate et al. (2006)7 conducted a subsequent study investigating ketamine’s
antidepressant effects, replicating the findings of Berman et al.6 with a larger sample size
and a study design that allowed for evaluation of a longer follow-up period. This study
was also a randomized, double-blind, placebo-controlled crossover study.7 A sample of
18 patients with TRD was enrolled to receive IV infusions of ketamine (0.5 mg/kg) and
saline placebo over 40 minutes, one week apart, in a crossover design. Selection criteria
were similar to those employed by Berman et al.,6 but subjects with comorbid psychiatric
disorders were not included. The primary outcome was changes in depression scores on
the 21-item HDRS from baseline to several time points following treatment. The
investigators defined a clinically significant response as a 50% or greater reduction in
HDRS scores from baseline, while clinical remission was defined as a score of 7 or lower
on the HDRS. A fixed-effects linear mixed model was utilized to analyze the differences
in depression scores following ketamine and placebo treatments over nine temporal data
points from baseline to follow-up at seven days.7
Significant drug effects (F1,203 = 58.24, p<0.001) and time effects (F8,203 = 9.48; p<0.001)
were observed, indicating a statistically significant benefit for ketamine over placebo in
reducing HDRS scores at all time points from 110 minutes post-infusion to seven days
post-infusion.7 The effect size was large at 24 hours post-infusion (d=1.46 [95% CI, 0.912.01]) and was moderate-to-large at one-week follow-up (d=0.68 [95% CI, 0.13-1.23]).
At 24 hours post-infusion, 71% of subjects receiving ketamine met criteria for a clinical
response, compared to 0% of subjects receiving placebo. Additionally, 29% of subjects
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receiving ketamine met criteria for clinical remission compared to 0% of subjects
receiving placebo. Among subjects who responded to ketamine, 35% maintained their
clinical response at one-week follow-up.7
The authors noted that no other depression treatment had yielded as robust a response
with a single treatment prior to their study.7 The clinical response to ketamine among
depressed subjects in this study was greater than response rates observed at 8 weeks for
bupropion (62%), selective serotonin reuptake inhibitors (63%), and venlafaxine (65%) in
systematic reviews.7 This trial replicated the findings of Berman et al.6 in a larger sample
with stricter exclusion criteria, demonstrating the robustness of ketamine’s clinical effects
in MDD. Importantly, it provided more detailed data regarding the rapid onset of
ketamine’s antidepressant effects and the course of improvement over a longer follow-up
period of seven days.
In addition to the trials conducted by Berman et al.6 and Zarate et al.7, several subsequent
trials have replicated the efficacy of a single IV infusion of ketamine in rapidly reducing
depressive symptoms in MDD as a primary treatment,8,9 as well as in bipolar
depression.10,11 Newport et al. (2015) conducted a systematic review examining six RCTs
which investigated the antidepressant effects of a single IV infusion of ketamine against a
placebo treatment.1 The authors concluded that a single IV infusion of ketamine at
0.5mg/kg over 40 minutes provided a statistically significant reduction in depressive
symptoms within 24 hours, with a composite odds ratio (OR) of 9.87 (95% CI=4.3722.29, z=5.50, p<0.001) for a clinically significant antidepressant response 24 hours after
receiving ketamine.1 This solidifies the strong evidence base supporting ketamine’s
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antidepressant effects when administered as a single treatment, and stimulated additional
research investigating strategies to prolong ketamine’s antidepressant effects.
Review of Empiric Studies Investigating the Efficacy of Repeated Ketamine
Infusions
Based on the findings of several blinded, randomized, placebo-controlled trials
demonstrating the efficacy of a single subanesthetic dose of ketamine as a rapid-acting
antidepressant of short duration, Murrough et al. (2013) conducted a novel open-label
study investigating the effects of repeated ketamine infusions on the time-course of its
antidepressant effects.5 Inclusion and exclusion criteria were similar to those employed
by Berman et al.6 and Zarate et al.7 Subjects were administered up to six IV infusions of
ketamine (0.5mg/kg) over 40 minutes, over a period of 12 days. The primary outcome
was changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from
baseline to follow-up. One of the defining aspects of this study was that subjects were
followed up for up to 83 days, representing a follow-up period several months longer
than what had been utilized in prior studies and allowing for a better evaluation of the
temporal course of ketamine’s antidepressant effects.5
Similarly to previous studies investigating the effects of a single ketamine infusion,6-9
71% of subjects demonstrated a clinically significant reduction in MADRS scores
following up to six ketamine treatments over 12 days.5 A significant and robust decrease
in MADRS scores was observed at two hours after the first ketamine infusion (18.9 +/6.6, p<0.001), which was generally maintained for the duration of the ketamine treatment
period as evidenced by a mean decrease in MADRS scores from 31.8 to 12.9 (p<.001).5
This replicated the finding from prior studies that statistically significant improvements
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in depression scores were first evident at two hours post-infusion in many subjects,6-9
with 94% of responders showing a significant response within four hours of receiving an
infusion.5 Among individuals that showed a significant response, the median time to
relapse of depressive symptoms to pre-treatment baseline levels was 18 days, with the
24th and 75th percentiles respectively being 11 days and 27 days. Importantly, this study
revealed that response within four hours of receiving a ketamine treatment was highly
predictive of response at study end (95% sensitive, 71% specific), providing important
implications regarding the early identification of likely responders to treatment going
forward.5
The selection criteria and methodology that was utilized was very similar to those utilized
by studies of ketamine as a single infusion,6-9 strengthening the internal validity of the
study and the generalizability of the results. Utilizing the MADRS as the primary
outcome improved the sensitivity of the results, given that the MADRS is better suited to
track changes in depression scores as a result of an intervention than the HDRS or the
Beck Depression Inventory (BDI).12 This study provided a significantly improved
characterization of the temporal scale of ketamine’s antidepressant effects, demonstrating
that ketamine’s effects were lost within 2-3 weeks of receiving an infusion in the majority
of responders.5 However, this study revealed that proportions of patients may relapse
sooner, while others enjoy a more prolonged antidepressant effect. The data presented in
this study provided preliminary evidence that repeated ketamine infusions may provide a
longer lasting antidepressant effect than that conferred by a single dose.
Singh et al. (2016) expanded upon the findings of Murrough et al.5 with a randomized,
double-blind, placebo-controlled, dose-frequency study investigating the effects of IV
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ketamine at different dose frequencies in subjects with TRD.13 Investigators enrolled 67
subjects and utilized similar selection criteria to previous studies.5-7 Subjects were
randomized to undergo one of four treatment regimens over a two week period: ketamine
twice per week, saline placebo twice per week, ketamine three times per week, or saline
placebo three times per week. Ketamine was administered according to the protocol
described previously.5-7 The primary outcome was mean change in MADRS scores from
baseline to day 15, after completion of ketamine therapy. Subjects were followed for an
additional two weeks following completion of two weeks of ketamine or placebo
treatments; MADRS scores were recorded daily during this time.13
Subjects who received ketamine twice per week showed a significantly greater mean
reduction in MADRS scores at day 15 compared to those receiving placebo (ketamine, 18.4 [SD=12.0]; placebo, -5.7 [SD=10.2]; p<.001).13 A similar significant mean reduction
in MADRS scores was observed in subjects receiving ketamine three times per week
compared to placebo (ketamine,

-17.7 [SD=7.3]; placebo, -3.1 [SD=5.7]; p<.001).

There was no significant difference in reductions in MADRS scores between groups
receiving ketamine twice per week and the group receiving ketamine three times per
week. Additionally, improvements in MADRS scores did not differ significantly between
groups at follow-up on day 29, indicating that twice-weekly dosing was sufficient to
provide a rapid and sustained antidepressant response as opposed to thrice-weekly dosing
that was studied by Murrough et al. previously.5 The authors conclude that twice-weekly
dosing would be preferable given these findings, since less frequent dosing would likely
reduce burden on patients and clinics, and reduce costs associated with treatment.13

20

This study has several limitations. The primary limitation was that a significant portion of
subjects did not complete the study due to loss to follow-up; 83.8% of patients completed
the first 15 days of the study, and only 36.8% of patients completed the entire 4-week
study. The authors report that the vast majority of subjects who discontinued prior to the
end of the study had withdrawn due to lack of efficacy of the saline placebo treatment.13
Furthermore, while this study provided valuable information regarding the dosefrequency characteristics of ketamine’s antidepressant effects, it was not powered to
detect a statistically significant difference between the two regimens.13 Due to the shorter
follow-up period than employed by Murrough et al.,5 conclusions cannot be drawn
regarding the longer-term duration of ketamine’s effects in each dose-frequency regimen.
The results of the study are reassuring overall in that they successfully replicated the
findings from Murrough et al.5 that ketamine’s effects seem to be prolonged with
repeated administration.
The evidence base for the efficacy of ketamine as a rapid-acting antidepressant is robust;
ketamine is the best studied and the most effective antidepressant among other
glutamatergic agents.2 Ketamine’s antidepressant effects have been shown to be superior
to a number of similar agents, including memantine, lanicemine, nitrous oxide,
traxoprodil, D-cycloserine, and rapastinel.1 The primary limitation to the utility of
ketamine as an antidepressant is its short duration of action. Studies of ketamine
administered in repeated doses demonstrate relapse rates of 55%-89% within one month
of receiving treatment, and to date there is a paucity of research investigating the
maintenance of its effects in the long-term.1 As a result, several authors have cited the
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need for future studies investigating strategies to enhance and prolong ketamine’s
antidepressant effects.1,5,13-17
Review of Empiric Trials Investigating Therapeutic Adjuncts to Ketamine for
Major Depressive Disorder
The short duration of ketamine’s antidepressant effects has generated interest in the
development of strategies to prolong its effects, which is desirable for a number of
reasons. Considering that ketamine’s antidepressant effects take effect much more
quickly and appear to be of greater magnitude than existing therapies for MDD, it is
unsurprising that its efficacy has generated research into developing strategies to
compensate for its shortcomings as an antidepressant drug. Reducing the amount of
treatments necessary to sustain its antidepressant effects would theoretically reduce the
risk of adverse effects associated with long-term use, reduce the abuse potential
associated with ketamine use, and reduce the costs associated with more frequent use.
However, there is currently a paucity of research regarding possible therapeutic
adjuncts.1This section will discuss the two RCTs that have been published to date
investigating possible adjuncts to ketamine to bolster its antidepressant effects.
Ibrahim et al. (2012) conducted a randomized, double-blind, parallel, placebo-controlled,
flexible-dose trial investigating whether ketamine’s antidepressant effects would be
prolonged with the addition of riluzole, a fellow NMDA-R antagonist which has been
shown to possess antidepressant and neuroplasticity-promoting effects via modulation of
glutamate activity, similar to ketamine.16 The investigators hypothesized that ketamine
and riluzole would exhibit synergistic effects given similarities in their mechanisms of
action. This study included 42 subjects with selection criteria similar to that described in
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previous studies.5,7,13 All subjects were administered a single IV infusion of ketamine
(0.5mg/kg) over 40 minutes in an open-label design; 4-6 hours after treatment, subjects
were randomized to receive riluzole (100-200mg/day) or placebo for four weeks. The
primary outcome was change in MADRS scores from baseline to various time points
following ketamine administration, as well as to daily MADRS scores for the subsequent
28 days.16
A linear mixed model was used to analyze the data, which showed significant reductions
in MADRS scores over the course of the study (F=8.81, d.f.=28, 297, p<.001).16 This was
an expected result given that all subjects received ketamine treatment, and is consistent
with effects demonstrated previously. However, the analysis failed to show a significant
difference between the treatment groups, or for the interaction between treatment groups
and time (treatment: F=0.00, d.f.=1, 40, P=0.99; time x treatment: F=1.20, d.f.=28, 297,
P=0.23).16 These results indicate that riluzole failed to potentiate ketamine’s
antidepressant effects. The linear mixed model failed to show significant interactions for
the secondary outcomes of scores on the BDI or HRDS.16
The generalizability of this study is limited by the fact that all subjects had been
hospitalized for treatment of their depression for 46 days prior to starting the study. The
authors hypothesized that the overlapping mechanisms of riluzole and ketamine may
have interfered with one another, rather than potentiate each other.16 However, the
authors noted that riluzole demonstrated a non-significant increase in time-to-relapse
compared to the placebo group (17.2 vs. 9.8 days), which may hold clinical significance
despite its lack of statistical significance. They additionally posed that the severity of
depressive symptoms in TRD may have masked the effects of riluzole.16
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More recently, Wilkinson et al. (2017) conducted an open-label study investigating
whether IV ketamine plus parallel treatment with cognitive behavioral therapy (CBT)
would produce antidepressant effects superior to those conferred by ketamine as a
solitary treatment.15 Specifically, this study sought to determine whether CBT could
prolong ketamine’s antidepressant effects or improve the therapeutic response in subjects
who do not demonstrate an initial response to ketamine treatment. All subjects underwent
IV ketamine infusions (0.5mg/kg over 40 minutes) twice per week for the first two weeks
of the study. All subjects additionally engaged in 12 sessions of CBT concurrently with
the ketamine treatments – two sessions per week during the first two weeks, then weekly
sessions during the subsequent 8 weeks. Subjects were followed for up to three months
following the ten-week study period. The primary outcome was the proportion of subjects
exhibiting a clinical response or remission, defined as a greater than 50% reduction in
baseline MADRS scores or a MADRS score less than 9, respectively.15
The results demonstrated that 43.8% of subjects achieved remission of depressive
symptoms, with 50% of subjects overall demonstrating a clinically significant response,15
similar to response rates reported previously.5-7,13 Subjects that demonstrated a response
to ketamine showed a significantly maintained response for the first three weeks of the
study, but failed to maintain a significant improvement in MADRS scores after three
weeks. The median time to relapse after ketamine treatment among subjects who
responded was 12 weeks, with only 25% of subjects (n=2) relapsing by 8 weeks.15
This represents a markedly prolonged antidepressant effect of ketamine compared to
those observed in previously published trials, but the small sample size and absence of a
control condition in this study limits interpretation and generalizability of this data.
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Additionally, the results may be confounded by the concurrent use of psychotropic
medications by study subjects, which may have caused overestimation of the true effect
of CBT in prolonging ketamine’s antidepressant effect; previous studies utilized a
“washout” period to control for this factor.5,7,13 Overall, the preliminary results of this
study are promising and suggest that CBT may enhance or prolong the duration of
ketamine’s antidepressant effects.
Limitations to Ketamine’s Use as an Antidepressant
While generally considered safe when administered at subanesthetic doses, ketamine
possesses sympathomimetic properties that cause transient elevations in heart rate and
blood pressure which represent a potential safety concern for certain patient
populations.17 One review of clinical trials using ketamine found that approximately 30%
of subjects receiving subanesthetic doses exhibited tachycardia >110 beats per minute,
systolic blood pressure readings >180mm Hg, or diastolic blood pressure readings
>110mm Hg.17 As a result of these properties ketamine should be used judiciously in
depressed populations with comorbid cardiovascular disease. 14
The two most notable adverse effects of subanesthetic doses of ketamine are transient
dissociation and psychotomimetic symptoms that are very commonly observed during
intravenous infusion,17 rendering it intolerable for a small proportion of individuals.3
Ketamine has a number of undesirable side effects, the most common of which are
dizziness, visual changes, drowsiness, impaired coordination, and “feelings of disconnect
from reality”.17 These adverse effects are most prominent two hours after receiving an
infusion, and typically resolve in 4-24 hours.17 However, these adverse effects have little
effect on the tolerability of ketamine; meta-analyses have shown that there are no
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significant differences between ketamine and control groups regarding all-cause
discontinuation.17 Furthermore, when side effects are considered to be clinically
significant, symptomatic treatment is often sufficient – for example, oral clonidine has
been used for hypertension prophylaxis.17
Ketamine’s psychotomimetic dissociative properties confer an abuse potential associated
with medical risks, further limiting its utility.3,17 Ketamine is commonly abused as a
“club drug”, with over 2 million teenagers and adults in the United States reporting they
had used ketamine recreationally in their lifetime in 2006 and abuse rates steadily
increasing worldwide in the past several decades.18 Chronic ketamine abuse – at doses
much higher than those used for depression – has been associated with neurotoxicity
including cognitive dysfunction, memory impairments, and white matter abnormalities,
as well as with severe urologic pathology.14
There is a large population of depressed individuals that may benefit from repeated
infusions ketamine, which at this point appears to be safe in the short term.14 Several
studies point to the need for future studies to evaluate the long-term safety of ketamine
use as well as strategies to mitigate its adverse effects and abuse potential.14
Review of the Antidepressant Effects of Exercise
The role of exercise as a treatment option for patients with MDD has historically been the
subject of debate; conflicting results in randomized controlled trials and meta-analyses
have led many to question the true benefit that exercise has on depressive symptoms in
MDD. There is considerable variation in the study populations, clinical settings,
methodologies, nature of exercise interventions, control groups, and statistical analyses
among RCTs that makes comparisons between studies difficult. Additionally, the vast
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and heterogeneous body of literature dedicated to the study of exercise in depression
further complicates comparisons between studies. This review will summarize high-level
evidence which supports exercise as having moderate antidepressant effects when utilized
as a primary treatment for MDD, as well as evidence that supports the efficacy of
exercise as an adjunct to standard psychological and pharmacological treatments.
A 2013 Cochrane Review performed a systematic review and meta-analysis of the
literature investigating the antidepressant effects of exercise against placebo,
psychological, and pharmacological control therapies.19 The investigators included RCTs
that were designed to directly compare exercise with standard therapy, placebo therapy,
or no therapy in adults that met diagnostic criteria for MDD. The authors reviewed 39
clinical trials that met inclusion criteria for the study, and extracted data from 37 of those
trials for meta-analysis. Using data from primary and secondary outcomes from these
trials, the authors calculated effect sizes and standardized mean differences to examine
the overall pooled effect of exercise on depression rating scores. The authors additionally
carried out several subgroup analyses to examine whether effect sizes were influenced by
type, frequency, or intensity of exercise.19
Among studies that compared exercise to either a control treatment or to no treatment,
analyses revealed a moderate clinical effect for exercise on depressive symptoms (SMD 0.62, 95% CI -0.81 to -0.42).19 Analyses of studies that examined the effects of exercise
at long-term follow-up showed a small effect favoring exercise (SMD -0.33, 95% CI 0.63 to -0.03). There was no significant difference between exercise and psychological
therapies (SMD -0.03, 95% CI -0.32 to 0.26) or between exercise and pharmacotherapy
(SMD -0.11, 95% CI -0.34 to 0.12). When the authors analyzed the six trials that they
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classified asr high quality studies (utilized adequate allocation concealment, blinded
outcome assessment, and intention-to-treat analysis), the effect of exercise on depressive
symptoms was not statistically significant (SMD -0.18, 95% CI 0.97 to 1.04).19
This study was one of the largest and most comprehensive reviews of the use of exercise
for depression. One of the key findings was that exercise was found to be no more
effective than psychological or pharmacological treatments in reducing depressive
symptoms, indicating that it is at least as effective as available treatments and is a viable
treatment option for patients with depression. Additionally, the authors concluded that
exercise had been shown to be moderately more effective than a control treatment in
improving the symptoms of MDD,19 indicating that for some patients exercise represents
a viable option for a primary depression treatment. This study found a small effect size
for the benefits of exercise at follow-up,19 indicating that the benefits of exercise seem to
persist after the cessation of an intervention, although it was unclear whether subjects
continued to exercise on their own during the follow-up phases of the included studies.
Ekkekakis20 published a comprehensive critical appraisal of the Cochrane review by
Cooney et al.19 Ekkekakis noted that the effect size for exercise in treating depression had
decreased by 44% from 2001 to 2013 (SMD of -1.10 to -0.62, respectively), with
sequential decreases in the SMD with each periodic update of the review.20 He argues
that this is a result of flawed selection criteria employed by Cooney et al. The central
argument supporting this assertion is that the authors included studies in which exercise
plus a standard treatment (psychotherapy or antidepressant medication) was compared to
standard treatment alone in “exercise versus no-treatment control” comparisons, which is
methodologically flawed and likely caused an underestimation of the effect size of
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exercise for depression.20 Additionally, Ekkekakis argues that the inclusion of trials
comparing exercise to interventions such as tai-chi or yoga would further underestimate
the efficacy of exercise as these treatments may influence depressive symptoms and are
not equivalent to inactive treatment.20 Subsequent meta-analyses incorporated Ekkekakis’
recommendations and found larger effect sizes for exercise in treating MDD.
Schuch et al. (2016) performed a subsequent meta-analysis on the antidepressant effects
of exercise while controlling for publication bias, which had not been done in previous
systematic reviews.21 Importantly, the inclusion criteria were designed based on
Ekkekakis’20 criticism of the flawed methodology utilized by Cooney et al.19 in the 2013
Cochrane review. The authors excluded studies in which exercise plus an established
treatment was compared to another established treatment,21 as Ekkekakis argued that this
likely led to the “shrinkage” of the pooled SMD observed in the study by Cooney et al.20
Furthermore, the authors excluded studies in which tai chi, yoga, or qi going were used as
control intervention as they utilize behaviors such as meditation and deep breathing that
have been shown to have an effect on depressive symptoms and may underestimate the
effects of exercise.21
The primary outcome of this study was the pooled mean change in depression scores
from baseline to post-exercise intervention, compared to changes in depression scores in
control groups, represented by the SMD.21 Trim and fill and fail-safe n analyses were also
utilized to control for publication bias. The authors reported a large effect size in favor of
exercise (SMD = 0.98, 95% CI 0.68 to 1.28, p < 0.001, Q = 135, p < 0.01). The effect
size was recalculated to control for publication bias with Dival and Tweedie’s trim and
fill method, revealing a larger effect size (SMD =1.11, 95% CI 0.79 to 1.23, p<0.001).
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Furthermore, the authors calculated a fail-safe number of 1,057 studies with negative
results for an exercise intervention required to nullify the significance of their results.21
After employing more rigorous inclusion criteria and controlling for publication bias, this
study reported a large effect size for exercise in reducing depressive symptoms when
compared to an inactive control group,21 which supports exercise as an effective primary
treatment for MDD. The authors attributed the larger effect size to their adaptation of
Ekkekakis’20 recommendations.21 The authors concluded that their analyses suggest that
publication bias typically led to an underestimation of the antidepressant effects of
exercise, and may have led to underestimation of the true effects of exercise on reducing
MDD symptoms in prior meta-analyses. The authors contend that their overall results
support the use of exercise as an evidence-based treatment for the treatment of MDD.21
Schuch et al. provided robust evidence supporting the use of exercise as a primary
treatment for MDD given its large effect size when compared to non-active controls.21
However, in order to determine the effect size of exercise as a primary treatment for
MDD, the authors excluded studies in which exercise plus standard treatment was
compared to standard treatment alone.21 While necessary for the goals of their study, this
precluded their study from evaluating the effects of exercise as an adjunct to standard
therapies such as medication or psychotherapy.
Kvam et al. (2016) conducted a meta-analysis examining the effects of exercise as either
a primary treatment or as an adjunct to antidepressant medication.22 The authors used
data to calculate effect sizes using random effects models. Similarly to Schuch et al.,21
the authors excluded studies in which tai-chi, or yoga were used as controls groups. The
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primary outcome was the calculation of effect sizes using Hedges’ g, representing the
difference between exercise and control groups in reducing depression scores.22
The authors reported a statistically significant, moderate to large effect of exercise over
all control conditions (g = -0.68, 95% CI -0.92 to -0.44, p<0.001). However, this effect
was small and no longer statistically significant at follow-up (g = -0.22, 95% CI -0.53 to
0.09, p = .16). The smaller effect size for exercise at follow-up is consistent with the
findings of Cooney et al.19 The authors suggest that the antidepressant effects of exercise
are likely of short duration and require continuous activity to maintain their effect, and in
many studies the exercise intervention ceased prior to follow-up.22 No comment was
made on whether compliance with exercise regimens was upheld during follow-up.
For part of their study, Kvam et al. investigated the effects of exercise against non-active
controls only. Similarly to Schuch et al., the authors found a large effect size favoring
exercise over no intervention (g = -1.24, 95% CI -1.83 to -0.65, p<0.001). They
additionally directly compared the effects of exercise on MDD to standard treatments,
including psychotherapy and antidepressant medication. Similarly to the findings of other
analyses,19,21 the authors found that there were small, non-significant effects for exercise
compared to psychotherapy (g = -0.22, 95% CI -0.65 to 0.21, p = .31) or antidepressant
medication (g = -0.08 (95% CI -0.33 to 0.18, p = .55),22 indicating that exercise is
comparable to either standard treatment for MDD.22
The authors analyzed four studies in which exercise was added as an adjunct to
antidepressant medication, and was the first meta-analysis to do so.22 Combination
therapy generated a moderate effect over medication alone that was not statistically
significant (g = 0.50, 95% CI -1.10 to 0.11, p = .11). The authors acknowledged the
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limited applicability of this figure given it was based on four studies and that further
research of combination therapy is warranted. Despite the limitations and need for future
studies, the authors contend that evidence supports the use of exercise as primary
treatment or as an adjunct to standard therapy for MDD.22
Babyak et al. (2000) conducted a study comparing the long-term antidepressant effects of
exercise, medication, and exercise plus medication;23 the results of this study were not
included in the meta-analysis by Kvam et al.22 Investigators enrolled 156 adults age 50 or
older with a diagnosis of MDD that had previously completed a study (A Study of
Medical Information and Lifestyles in Eindhoven, “SMILE”)24 in which they underwent
four months of treatment with aerobic exercise, sertraline (50-200mg/day), or aerobic
exercise plus sertraline (50-200mg/day). The SMILE study compared depression scores
at baseline and at four months with the primary outcome being mean changes in the
HDRS.24 While patients in the medication group showed improvements in depression
scores more quickly, there were no statistically or clinically significant differences
between groups at the end of the four-month study.24 All three treatment groups
demonstrated significant reductions in depression scores at four months which were not
significantly different (exercise group, 60.4%; sertraline group, 65.5%; combination
group, 68.8%; p = .67).24 Babyak et al. sought to investigate the impact of continued
exercise beyond the study period on depressive symptoms at long-term follow-up, ten
months after completion of the SMILE study.23
At 10-month follow-up, subjects in the exercise-only group demonstrated significantly
lower rates of MDD (exercise, 30%; sertraline, 52%; combination, 55%; p = .028) and
increased likelihood of being in either partial or full remission (OR = 6.10, p = .01) than
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subjects in the other two study groups.23 64% of subjects in the exercise group and 66%
of subjects in the combination group continued to exercise, while 48% of subjects in the
sertraline groups started to exercise during the follow-up period. Multiple logistic
regression analysis revealed that among subjects from all three groups, those who
exercised regularly during the follow-up period were significantly less likely to meet
diagnostic criteria for MDD at 10-month follow-up (p<.0009); this figure included
adjustments for baseline depression, age, gender, and antidepressant use during the
follow-up period.23
This study represents lower-level evidence that exercise appears to be at least as
efficacious as antidepressant medication in the treatment of MDD, which was supported
in the meta-analyses reviewed previously.19,21,22 Additionally, subjects in the exercise
group demonstrated significantly lower likelihood of relapse and higher likelihood of
remission at ten-month follow-up.23 Importantly, regular exercise during the follow-up
period was associated with a lower likelihood of relapse at follow-up,23 indicating that
exercise may have a role in prolonging the antidepressant effects of treatments with
shorter duration, such as psychotherapy or ketamine. Exercise did not augment the effects
of antidepressant medication in this study,23 which limits the generalizability of exercise
as a potential adjunct to other standard treatments. However, it was noted that a number
of subjects spontaneously reported that they felt that sertraline interfered with the benefits
of exercise. It is conceivable that the commonly reported side effects of sertraline such as
fatigue or drowsiness25 contributed to this and interfered with synergy between exercise
and medication.22 These adverse effects have not been reported in subjects receiving
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ketamine therapy, rendering it unlikely that ketamine’s effects would negate the benefits
of exercise.
Review of Relevant Methodology
The following section will review the methodology that has been employed in prior
studies and justify the methodology to be used in the present proposal.
Study Design
The proposed study will be a single-blind, randomized controlled trial comparing
ketamine to ketamine plus an exercise regimen for the treatment of MDD in an adult
population. The use of an RCT design is consistent with previous trials investigating the
antidepressant effects of ketamine as both a single infusion6,7 and as repeated
infusions,5,13 and is also consistent with the design of numerous studies examining the
antidepressant effects of exercise as a primary treatment or as an adjunct to standard
treatments.19,21-23,26 The use of an RCT design in this study will optimize our ability to
directly observe the impact of the addition of exercise regimens to established ketamine
treatment protocols.
Unlike previous studies investigating the antidepressant effects of ketamine and exercise,
the present study will not utilize a placebo control. The primary purpose of this study is
to investigate whether exercise regimens augment the antidepressant effects of ketamine,
and the study is designed to compare ketamine treatment alone to ketamine plus an
exercise regimen in a similar population. Given that placebo controls for exercise such as
yoga, stretching, and mindfulness have been demonstrated to influence depression
symptoms and may confound results,20 a placebo control for exercise will not be utilized
in this study. Instead, ketamine treatment alone will serve as a control group.
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Study Population
The population that will be recruited for this study includes male and female adults, ages
18-65, that meet criteria for a clinical diagnosis of MDD based on criteria outlined in the
DSM-5. The severity of depression will be moderate-severe, as measured by a score ≥20
on the MADRS, in order to target a population most likely to respond to the exercise
intervention. The population for this study was adapted from a number of RCTs
investigating the antidepressant effects of ketamine.5-7,13,23,26 In the exercise literature,
older adults were included in several trials but an upper age limit will be employed in this
study given concerns regarding the safety of ketamine use in older populations.17
Selection Criteria
The present study will utilize selection criteria based on methodology previously reported
in a number of RCTs investigating the antidepressant effects of ketamine. These trials
were all designed in a similar fashion and utilized a very similar set of inclusion and
exclusion criteria.5-7,13,23,26 The inclusion criteria that will be employed in the present
study will include a current diagnosis of MDD according to DSM-5, a current major
depressive episode (MDE) of at least four weeks duration, moderate-severe depression as
measured by a score ≥20 on the MADRS, and being free of antidepressant medication for
at least 2-4 weeks. Additionally, all subjects must demonstrate good overall health as
evidenced by a comprehensive medical history, physical exam, and routine diagnostic
studies.5-7,13,23,26
The exclusion criteria will include a history of bipolar disorder or psychosis, a substance
use disorder within the past three months (with the exception of tobacco use), medical
contraindication to exercise, and current use of antidepressant medication.5-7,13,23,26 An
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additional inclusion criterion that will be employed is a low-active lifestyle, defined as
performing less than 20 minutes of exercise less than three times per week, in order to
target a population most likely to benefit from exercise.27,28 The present study will enroll
subjects with MDD rather than those with TRD, given that the vast majority of the
literature on the antidepressant effects of exercise has been studied in MDD, and sparse
evidence for the efficacy of exercise for TRD exists.
Exercise Intervention
There is a significant degree of variation in the type, intensity, frequency, duration, and
setting of exercise interventions for MDD that have been studied in RCTs. As a result of
this variation, the methodology for the present study will be adapted from evidence from
systematic reviews and meta-analyses that provide higher-level evidence supporting the
use of particular exercise interventions.19,21,22,29-32 For the exercise intervention in this
study, subjects will ride on stationary bicycles at a moderate intensity, for 45-minute
sessions, three times per week, for a total duration of three months. These parameters
have been associated with the greatest effect sizes of exercise in reducing depressive
symptoms.19,21,22,29-32 The exercise sessions will occur in a group setting under the
supervision of a qualified fitness professional, which has been shown to improve
compliance.19,21,22,27,31,33
The definition of moderate intensity exercise will be adapted from the American College
of Sports Medicine (ACSM). The ACSM defines moderate intensity exercise as activity
that occurs at 64-76% of an individual’s estimated maximum heart rate (HR).34 The
ACSM states that an acceptable method for estimating maximum HR is using the
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equation, (Max HR = 220 – age).34 The stationary cycling that will be utilized in this
study complies with the definition of exercise as outlined by the ACSM.34
The exercise intervention in this study will begin one day after the administration of the
first ketamine treatment, in order to optimize the potential synergy between the two
treatments without affecting baseline depression scores prior to the first ketamine
treatment. Subjects in the ketamine plus exercise group will continue their exercise
regimen throughout the follow-up phase because doing so has been associated with an
increased likelihood of being in partial or full remission from an MDE.23,26
Ketamine Control
All subjects in this study will be administered ketamine according to a standardized dose,
route, frequency, and duration. All of the studies cited previously administered ketamine
as an intravenous infusion, at a dose of 0.5mg/kg delivered over a 40-minute period.1,2,57,13

This protocol will be adapted for the present study.

All subjects will receive three ketamine infusions per week for two consecutive weeks,
over a total period of 12 days. This is based on the frequency outlined by Murrough et
al.5 This contrasts with data from Singh et al., who demonstrated that administration of
ketamine twice per week for two weeks did not appear inferior to the protocol outlined by
Murrough et al.13 However, the study by Murrough et al. was designed with a
significantly longer follow-up period which provided a more robust characterization of
the temporal scale of ketamine’s antidepressant effects. Therefore, the schedule studied
by Murrough et al. will be adopted for this study.5
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Primary and Secondary Outcomes
The primary outcome in the present study will be the mean change in MADRS scores
from a pre-treatment baseline to scores at four weeks of follow-up from the last ketamine
infusion. Two previous studies measured changes in MADRS scores from baseline to the
end of a two week period of repeated ketamine infusions as their primary outcome.5,13
However, these studies were designed to detect the efficacy of repeated infusions of
ketamine in reducing depressive symptoms over a two week period. Change in MADRS
scores was also the primary outcome in the study by Ibrahim et al. which investigated
riluzole as an adjunct to ketamine therapy.16 Since our study is designed to detect the
efficacy of exercise as an adjunct to enhance and prolong ketamine’s antidepressant
effects, we will compare baseline MADRS scores to those taken four weeks after the last
ketamine treatment. The time point of four weeks was selected based on the observation
that ketamine’s antidepressant effects had subsided by 27 days in the majority of subjects
in two prior trials studying repeated infusions of ketamine over a two week period.5,13
A secondary outcome of interest will be the time to extinction of observed reductions in
MADRS scores as measured by Kaplan-Meier analysis.16 Extinction will be defined as a
relapse to a ≤50% reduction of an individual’s baseline MADRS score; this was the
definition of relapse utilized in a number of previous studies.5,13,16 Additional secondary
outcomes will include the Beck Depression Inventory-II (BDI-II), ClinicianAdministered Dissociative States Scale (CADSS), Brief Psychiatric Rating Scale
(BPRS), and Visual Analog Scale of Mood States (VAS). The BDI-II provides a
comparison measure to changes in MADRS scores, while the CADSS, BPRS, and VAS
are measured to evaluate the psychotomimetic effects of ketamine on subjects during and
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following infusions. This is most consistent with secondary outcomes employed in
numerous past studies investigating ketamine’s antidepressant effects.5-7,13,16,23
Sample Size
This study will utilize an alpha of 5% and a beta of 20% to power the study to 80%,
similar to previous trials evaluating exercise as a treatment for MDD.28 We aim to detect
a 9.5% difference in mean reductions in MADRS scores between the two groups, which
has been demonstrated to be a statistically significant reduction in MADRS scores in a
prior study comparing exercise to mind-body awareness as adjuncts to antidepressant
medication.35 This is similar to the effect sizes reported for exercise in reducing
depressive symptoms when compared to other active treatments in several metaanalyses.19,21,22 This effect size is above the minimum clinically important difference
(MCID) that has been documented for the MADRS scale.36 We anticipate a 15% loss to
follow-up based on prior studies and will correct the sample size for this variable.35,37
Calculations for the sample size are in Appendix I.
Statistical Analysis
There is a significant degree of variation in the methodologies utilized for statistical
analysis in the literature for both ketamine and exercise for depression. The primary
outcome of mean change in MADRS scores will be analyzed with paired t-tests and
repeated measures analysis of variance (ANOVA), comparing baseline scores to scores
measured four weeks following the last ketamine infusion. The secondary outcome of
scores on the BDI-II will be analyzed with the same methodology. This is most similar to
the methods employed by studies of exercise as an adjunct to standard treatments for
depression.28
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The secondary outcome of time to extinction of observed reductions in MADRS scores
will be analyzed with Kaplan-Meier analysis.16 Extinction will be defined as a relapse to
a ≤50% reduction from an individual’s baseline MADRS scores; this was the definition
of relapse utilized in a number of previous studies.5,13,16
Review of Possible Confounders
This study is designed to optimally control for factors that may confound the results.
Both the ketamine and exercise interventions were designed such that all subjects
undergo as similar a treatment as possible. All subjects in both study groups will receive
ketamine at the same dose, route, duration, and frequency. Some past studies were
flexible in allowing subjects to determine the intensity of exercise they performed in
clinical trials31; the internal and external validity of these studies were limited as a result
of the variability in exercise regimens that subjects performed. The exercise intervention
for this study was designed such that all subjects in the ketamine plus exercise group
undergo exercise of the same type, intensity, duration, and frequency to control for
confounding factors.
Past studies have utilized control conditions such as yoga, tai chi, meditation, and
stretching under the assumption that they represent an inactive control group. However,
subsequent studies have demonstrated that these behaviors may influence depression
scores and therefore represent a source of confounding.20-22 For this reason, the present
study will not utilize an active control group as a direct comparison to exercise.
Concomitant use of antidepressant medications represents another possible source of
confounding. Several past studies investigating ketamine for depression utilized a
“washout” period in which all antidepressant medications were discontinued for two
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weeks (four weeks for fluoxetine) prior to beginning ketamine treatment.5,7,13 Similarly,
the present study will require subjects to discontinue antidepressant medications for a
period of time prior to starting the study. The use of other psychotropic medication will
be permitted but will be measured as a baseline demographic in order to ensure that both
study groups are as similar as possible regarding concomitant use of medication.
Variation in baseline activity levels would likely confound the changes in depression
scores in subjects in the ketamine plus exercise group. In order to control for this factor,
this study will utilize sedentary lifestyle as a selection criterion. This was adapted from
prior studies that defined a low-active lifestyle as receiving less than 20 minutes of
exercise, less than three times per week.27,28
Conclusion
In this chapter, we reviewed the efficacy of ketamine as a rapid-acting antidepressant,
both as a single infusion and as a series of repeated infusions over a period of
approximately two weeks. The utility of ketamine as an antidepressant agent is limited by
its short duration, with most individuals experiencing a recurrence of depressive
symptoms within two weeks of their last dose. Furthermore, ketamine’s utility is limited
by concerns for abuse and its safety when used in the long-term.
In order to address the shortcomings of ketamine’s antidepressant effects, two strategies
have been investigated as possible therapeutic adjuncts to ketamine to prolong its
antidepressant response. The results have been mixed, but preliminary evidence suggests
that ketamine’s antidepressant effects may be amenable to augmentation strategies.
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Exercise has been proven to possess antidepressant effects that are comparable to existing
psychological and pharmacologic treatments for depression but come without the adverse
effects of medication or the costs associated with psychotherapy. Research has indicated
that moderate to vigorous aerobic exercise of at least 30 minutes duration, performed
under supervision of an exercise professional 3-4 times per week, for a period of at least
three months provides optimal improvement in depressive symptoms in adults with MDD
and may be an effective augmentation strategy when used with existing depression
treatments. The current proposal will be designed to evaluate the efficacy of aerobic
exercise as a therapeutic adjunct to potentiate or prolong the antidepressant effects of
ketamine therapy for the treatment of moderate-severe MDD in adults.
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CHAPTER 3: METHODS
Study Design
The proposed study will be a prospective, single-blind, randomized controlled trial (RCT)
investigating whether the addition of exercise regimens will prolong or potentiate the
antidepressant effects of ketamine in a population of adults with major depressive
disorder (MDD). This study is specifically designed to compare changes in depression
scores between two study groups: one group receiving ketamine treatment and a second
group receiving ketamine treatment plus an exercise regimen to perform (subsequently
referred to as the “ketamine only” and “ketamine plus exercise” groups, respectively).
Depression scores measured at baseline will be compared to scores following treatment
and scores throughout a three-month follow-up period.
This study will be carried out in two phases. Phase I will be the ketamine treatment
phase. During Phase I, all subjects in both study groups will receive intravenous (IV)
ketamine infusions three times per week for a total of two weeks. The subjects in the
exercise group will begin their exercise regimens at the beginning of this phase. Phase II
will be the three-month follow-up phase. During Phase II, the subjects in the ketamine
group will not undergo any additional treatment but will report to the clinic for evaluation
once per week for four weeks, and subsequently every other week for eight weeks during
the remainder of the follow-up period. The subjects in the exercise group will continue
their exercise regimens and will also report for evaluation according to the same schedule
without receiving any additional ketamine treatments.
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Study Population and Sampling
The study population will include adult males and females ages 18-65 with a diagnosis of
moderate-severe MDD that live in the state of Connecticut. Convenience sampling will
be utilized to obtain the study population, in order to facilitate the operationalization of
the recruitment process. Subjects will be sampled from outpatient primary care and
psychiatry clinics in New Haven and Fairfield counties.
Selection Criteria
Inclusion criteria will include meeting criteria for diagnosis of MDD according to
diagnostic criteria within the DSM-5, current major depressive episode (MDE) of at least
four weeks duration, a score ≥ 20 on the Montgomery-Åsberg Depression Rating Scale
(MADRS), and low-active lifestyle defined as < 20 minutes of exercise < 3 times per
week) Additionally, all subjects must be in good health as determined by a
comprehensive medical history, physical exam, urinalysis, urine toxicology screen,
electrocardiogram, complete blood count, and basic metabolic panel.
Exclusion criteria will include a lifetime history of bipolar disorder or psychotic disorder,
substance use disorder in the past three months (with the exception of tobacco use),
medical conditions precluding participation in exercise, medical contraindication to
receiving ketamine, current use of antidepressant medication, and pregnant or nursing
women. Other comorbid psychiatric disorders will be permitted if MDD is determined to
be the primary complaint.
Subject Protection and Confidentiality
The proposed study will require the approval of the Institutional Review Board (IRB)
through the Yale University Human Investigation Committee (HIC). All study personnel
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will be required to complete Yale Human Subjects Protection training as well as training
on the Health insurance Portability and Accountability Act (HIPAA). Only pertinent
subject identifiers will be collected. All confidential patient information and data to be
collected will be stored on secured networks with password protection. Informed consent
will be obtained from all subjects prior to enrollment in the study. Subjects will be
informed that their participation is entirely voluntary and that they may withdraw from
the study at any time.
Recruitment
Subjects will be recruited with the use of advertisements placed at local hospitals,
outpatient primary care and psychiatry clinics, local psychotherapy practices, local
universities, local grocery stores, online, and in local newspapers. Subjects will also be
recruited on the basis of referrals from local physicians and advanced practice
practitioners.
Study Variables and Measures
Independent Variable
The independent variable in this study will be the prescription of an exercise regimen,
which will only be prescribed to the exercise study group. Subjects in the exercise group
will begin exercising the day after their first ketamine infusion and will continue
exercising throughout the follow-up period. Subjects in the ketamine only group will be
instructed to maintain their usual baseline activity levels during both phases of the study.
The exercise intervention will be performed in a group setting and will be supervised by
an exercise physiologist. Subjects will be encouraged to ride on stationary bicycles in 40-
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minute sessions, at a moderate intensity (64-76% of estimated maximum heart rate), three
times per week. The stationary bicycles will be equipped with heart rate monitors for
continuous biofeedback during sessions, allowing subjects to titrate their efforts to
maintain moderate intensity exercise throughout the session to the best of their ability.
Dependent Variable
The dependent variable in this study will be changes in baseline MADRS scores at
various time points following ketamine infusions and throughout the follow-up period.
Control Condition
The control condition in this study will be the prescription of ketamine infusions.
Subjects in both study groups will receive ketamine treatments of the same dose, route,
duration, and frequency. For each individual treatment, ketamine will be administered
intravenously at a dose of 0.5mg/kg over a period of 40 minutes. All subjects will receive
a ketamine infusion three times per week for two weeks, in the first two weeks of the
study (Phase I).
Primary and Secondary Outcomes
The primary outcome will be the mean change in MADRS scores from baseline to scores
at four weeks after the last ketamine treatment. Secondary outcomes will include time to
extinction of reductions in MADRS scores during follow-up, mean change in MADRS
scores from pre-treatment baseline to post-treatment follow-up at study day 13 (24 hours
after the final ketamine treatment), suicidality (as a separate item on the MADRS), and
scores on the Visual Analog Scale of Mood States (VAS), Clinician-Administered
Dissociative States Scale (CADSS), Brief Psychiatric Rating Scale (BPRS), and the Beck
Depression Inventory-II (BDI-II) measured throughout the study.
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Baseline characteristics
The following baseline characteristics will be measured prior to the start of the study:
age, sex, race, years since initial diagnosis of MDD, number of lifelong MDEs, duration
of present MDE, number of past treatments, prior antidepressant use, current
medications, comorbid psychiatric disorders, baseline MADRS scores, BMI, and lifetime
substance use disorder.
Methodology Considerations
Blinding of Intervention: Subjects will not be blinded to the exercise intervention, given
that it will not be feasible to blind subjects to whether or not they are exercising.
Evaluators will be blinded to the study groups that subjects have been assigned to.
Blinding of Outcome: All evaluators will be blinded to the primary and secondary
outcomes.
Assignment of Intervention: Subjects will be randomly allocated to either the ketamine
only group or the ketamine plus exercise group, in a 1:1 fashion, using a computergenerated algorithm.
Adherence: Adherence with exercise regimens will be monitored by several certified
exercise physiologists, who will be present at all exercise sessions throughout the study
and will take attendance and also monitor subjects’ heart rate during exercise sessions.
Adherence with ketamine treatments will be monitored by the research nurse at infusion
appointments.
Adverse events: Psychotomimetic effects will be measured using the VAS, CADSS, and
BPRS. All adverse effects of ketamine treatment will be recorded by the research nurse.
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All adverse events related to the exercise intervention will be documented by the exercise
physiologist.
Data Collection
Subject eligibility will first be assessed via telephone screening and by a preliminary
medical record review. At the screening visit, our research team will explain the overall
study plan to potential subjects and review the consent form. Subjects will have an initial
screening evaluation that will include psychiatric history, medical history, physical
examination, and laboratory assessment. Other detailed procedures are described in Table
1. If the examination and test results are acceptable and the subject meets the inclusion
and exclusion criteria, the subject will be invited to the 6 ketamine infusion visits. During
the ketamine infusion sessions, rating scales (MADRS, BDI-II, BPRS, CADSS, VAS)
will be measured at -60, 0, +60, and +240 minutes. The exercise intervention in the
ketamine plus exercise group will begin one day after the first ketamine treatment will
continue throughout the follow-up phase.
Sample Size Calculation
This study will utilize two-sided hypothesis testing with an alpha of 5% and a beta of
20%, which will power the study to 80%. We aim to detect a 9.5% difference in mean
reductions in MADRS scores between ketamine treatment alone and ketamine treatment
plus an exercise regimen at four weeks post-treatment.1 Based on these parameters, we
will require a sample size of 52 total subjects, with 26 subjects assigned to each study
group. The sample size was calculated using Power and Precision software (Power and
Precision. Version 4. Biostat, Inc. Englewood, NJ). We anticipate a 15% loss to follow-
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up; correction for this variable leads to a total sample size of 60 subjects with 30 subjects
per treatment group. Calculations for the sample size can be found in Appendix I.
Table 1. Procedures involved from screening visit to visit 16
Phase I
(Ketamine treatment)
1
Visit
Day
Exercise intervention
Ketamine Infusions
Informed Consent
Inclusion/Exclusion
Demographics
SCID
Psychiatric Evaluation
Physical Exam
CBC, Chemistry, Urinalysis
Urine toxicology/pregnancy
BP, Pulse
MADRS, BDI-II
BPRS, CADSS, VAS
Adverse Event

7

8

9-12

13-16

F/U

Weekly

Q 2 weeks

12

13

X

3 5 8 10
3 times a week
X X X X

X
X
X
X

X
X
X
X

X
X
X
X

Screeni
ng

2

3

-14-0

1

X
X
X
X
X
X
X
X
X
X

Phase II
(3-month follow-up)

4

X
X
X
X

5

X
X
X
X

6

X
X
X
X

19,26,33 54, 68, 82,
,40
94
3 times a week

X

X

X

X

X

X

X

Abbreviations: Structured Clinical Interview (SCID), Montgomery- Åsberg Depression Rating
Scale (MADRS), Beck Depression Inventory-II (BDI-II), Brief Psychiatric Rating Scale (BPRS),
Clinician-Administered Dissociative States Scale (CADSS), Visual Analog Scale (VAS) of Mood
States, Complete Blood Count (CBC), blood pressure (BP)

Statistical Analysis
All data collected in the proposed study will be analyzed using an intention-to-treat
protocol. P-values <0.05 will be considered statistically significant for all analyses. All
statistical analyses will be performed using the Statistical Package for the Social Sciences
(IBM; SPSS version 25). The primary outcome of mean change in MADRS scores will
be analyzed using a paired t-test, which will compare MADRS scores measured at
baseline to those measured at four weeks following the last ketamine infusion. The
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secondary outcome of time to extinction of observed reductions in MADRS scores will
be analyzed using Kaplan-Meier analysis. This will measure MADRS scores throughout
the entire three-month follow-up period. This measure will be a dichotomous outcome
defined by whether subjects maintained a >50% reduction in baseline MADRS scores
periodically throughout the follow-up period of the study. An additional secondary
outcome of mean reduction in MADRS scores between groups after the completion of
Phase I (ketamine treatment) will be analyzed with a paired t-test. The secondary
outcomes of scores on the VAS, CADSS, BPRS, and BDI-II will be measured with
paired t-tests. Baseline characteristics between groups will be analyzed appropriately;
continuous variables will be analyzed with paired t-tests and categorical variables will be
analyzed with Chi-Square tests. Analysis of Variance (ANOVA) will be performed on
any differences in baseline characteristics that are found to be statistically significant
following randomization of study groups.
Timeline and Resources
We plan to complete this study in 26 months as follows: (a) IRB approval and training
research staff (3 months), (b) recruitment of 60 subjects (20 months; 3 subjects/month),
and (c) data analysis and manuscript preparation (3 months). The Co-Principal
Investigators (physician assistant student and psychiatrist) will be responsible for project
oversight, clinical oversight, medical evaluation, recruitment, infusion day procedures,
data analyses, and manuscript preparation. Three research assistants will be responsible
for recruitment, scheduling, orienting, and consenting subjects, administering self-rated
rating scales, coordinating laboratory work, working with the investigational pharmacy,
and overseeing the accuracy of the record form. The administration of ketamine to
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subjects will require the assistance of a registered nurse. A pharmacist will be required
for the preparation and allocation of ketamine infusions to study subjects. Four exercise
physiologists will be required to supervise subjects undergoing exercise routines. A
statistician will be utilized to lead data analysis for the study.
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CHAPTER 4: CONCLUSION
Advantages and Disadvantages
The design of this study provides a number of advantages that optimize the probability of
providing positive results to confirm the study hypothesis. The utilization of a
randomized controlled trial (RCT) design allows for direct observation and measurement
of the efficacy of exercise as an adjunct to ketamine treatment for major depressive
disorder (MDD), and is consistent with prior trials investigating the antidepressant effects
of both ketamine and exercise. The use of the Montgomery-Åsberg Depression Rating
Scale (MADRS) as the primary outcome is best suited to track changes in depression
scores in the setting of antidepressant treatment.1
The internal validity of this study is strengthened by rigorous inclusion criteria that are
designed to target a population that is most likely to respond to exercise as a treatment for
MDD while balancing control for possible confounders. Specifically, the inclusion of
adults with baseline MADRS scores ≥20 and low baseline activity levels will enhance the
probability of demonstrating a clinically significant response to exercise.
The exclusion criteria are primarily designed to control for confounding factors. The
exclusion of subjects with comorbid psychiatric disorders, history of recent substance use
disorder, and medical contraindication to exercise strengthens the internal validity of the
study but simultaneously limits the generalizability of its results given that MDD may be
comorbid with any of these conditions. The exclusion of subjects currently using
antidepressant medication is necessary to most closely examine the true antidepressant
effects of ketamine with exercise.
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The exercise regimen to be utilized in this study is most consistent with research
literature that specifically demonstrates antidepressant effects in adults with MDD. This
regimen was tailored to the type, frequency, duration, and setting of exercise that has
shown the largest antidepressant effects in the literature.2-8 The protocol of ketamine
treatments is also adapted directly from a series of studies that consistently demonstrated
ketamine’s antidepressant effects,9-14 allowing for close evaluation of whether exercise
augments ketamine therapy for MDD.
This study has several limitations. The most significant limitation in the design of this
study is that it is not a placebo-controlled, double-blind study. This study is designed to
evaluate the efficacy of exercise as an adjunct to ketamine treatment, and is not designed
to evaluate the efficacy of ketamine given that its antidepressant effects are wellestablished; for this reason, ketamine treatment alone was chosen as the control
condition. The study was not blinded given that it is not practical to blind subjects to
whether or not they are physically exercising, and comparison conditions such as yoga,
tai chi, and stretching have been shown to influence depressive symptoms and potentially
underestimate the effect of exercise.3,15 However, evaluators will be blinded to the study
groups that subjects have been assigned to.
The use of exercise professionals to supervise exercise sessions was employed based on
findings that it improves compliance and provides for greater improvements in depressive
symptoms in prior studies.2-4,7,16,17 However, in real-world settings the use of fitness
instructors can be costly and may hinder access to exercise, decreasing the
generalizability of our results.
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Finally, there are concerns with the use of ketamine to treat MDD given its abuse
potential. Ketamine infusions will be administered in a supervised research setting,
minimizing the potential for abuse in study subjects. Additionally, subjects with a history
of substance use disorders will be excluded to improve validity and reduce confounding.
Other concerns include the acute side effect profile of ketamine. As with any medication,
investigators will educate patients about the risks and benefits of ketamine treatment and
patients with contraindications to ketamine use will be excluded from the study.
Clinical Significance and Implications
The primary implications of this study surround the possibility of augmenting and
prolonging ketamine’s antidepressant effects, which is desirable for several reasons.
Given its short duration, ketamine would need to be administered frequently to sustain its
antidepressant effects in the long-term. The adverse effects of long-term ketamine use are
unknown, and questions remain regarding its abuse potential. The ability to administer
ketamine less frequently is therefore desirable, and this could be achieved by prolonging
its effects with an augmentation strategy such as adjunct exercise regimens. Less frequent
administration of ketamine would also theoretically reduce the cost and improve
convenience for patients.
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APPENDIX
Appendix I: Sample Size Calculations

k = n2 / n1 = 1
n1 = (σ21 + σ22/K)(z1−α/2 + z1−β)2 / Δ2
n1 = (7.32 + 7.32/1)(1.96 + 0.84)2 / 5.72
n1 = 26
n2 = K∗n1 = 26
Δ = |μ2-μ1| = absolute difference between two means
σ1, σ2 = variance of mean #1 and #2
n1 = sample size for group #1
n2 = sample size for group #2
α = probability of type I error
β = probability of type II error
z = critical Z value for a given α or β
k = ratio of sample size for group #2 to group #1
Correction for anticipated loss to follow-up:
We anticipate 15% loss to follow-up based on prior studies.
0.15 * 52 = 7.8

→

52 + 7.8 = 59.8

We will round up for total sample size of n= 60, providing 30 subjects per study group.
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Appendix II: Montgomery-Åsberg Depression Rating Scale (MADRS)
The following was adapted from the original publication of the MADRS by Montgomery
and Åsberg (1979).7
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Appendix III: Clinician-Administered Dissociative Symptoms Scale (CADSS)
The following table represents an example of the questions that appear on the CADSS,
adapted from Bremner et al. (1998).59

62

Appendix IV: Brief Psychiatric Rating Scale (BPRS)
Adapted from the original publication of the BPRS by Overall et al. (1962).60
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Appendix V: Beck Depression Inventory-II (BDI-II)
Adapted from the Manual for the Beck Depression Inventory-II.61
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